In a recent study, Malavasi et al. [1] describe the prevalence and predictive factors for anticoagulant use in a cohort of patients with atrial fibrillation (AF) and cancer admitted into an oncology unit. Their main findings are that 1) 8.4% of the more than 4500 patients had AF. 2) that only 41% of patients received full-dose anticoagulation and, of those, almost 80% received low molecular weight heparin (LMWH) while an additional 35% received prophylactic-dose LMWH. 3) that anticoagulant use was not predicted by either cancer type or stage or CHA2DS2VASC and 4) that the use of anticoagulants did not impact overall survival.
